Applications of Tert-Butyl (3S,4R)-4-(2-Methoxyphenyl)Pyrrolidin-3-Ylcarbamate in Industrial Manufacturing

Tert-Butyl (3S,4R)-4-(2-Methoxyphenyl)Pyrrolidin-3-Ylcarbamate serves as a precision intermediate in complex molecule production, especially where stereochemical purity is critical for downstream synthesis. Our production adheres to stringent quality management systems so downstream partners in pharmaceutical and fine chemical industries can integrate it smoothly according to specific formulation and regulatory requirements. The following are the validated industrial applications of this intermediate in B2B manufacturing settings.

1. API Intermediate for Chiral Drug Synthesis

Pharmaceutical active ingredient manufacturers rely on this compound as a stereochemically defined building block for producing targeted chiral drug molecules, particularly in the CNS and neuroactive compound segments. Its use reduces racemization and streamlines multi-stage API synthesis by offering enhanced control in asymmetric hydrogenation or amide coupling steps.

Industry compliance standards

• ICH Q7: Good Manufacturing Practice for Active Pharmaceutical Ingredients
• USP-NF, EP, JP monograph requirements for chiral intermediates
• FDA 21 CFR Part 211 (for process traceability and documentation)
• EDQM guidelines for impurities and residual solvents

Typical usage ratio

• 0.15–0.45 molar equivalents in single-stage or telescoped reactions; adjusted based on target molecule yield and desired stereoselectivity

Downstream process integration

• Charged after initial ring closure or in the stage preceding asymmetric reduction, fully incorporated during amide bond formation via carbodiimide coupling or employed as the core scaffold in final chiral resolution steps

Final product types

• Enantiopure APIs for neurological disease treatments
• Stereospecific pharmaceutical intermediates
• Research-grade neuroactive reference standards

2. Precursor for Investigational New Drug (IND) Compound Libraries

CROs and biotech firms engaged in drug discovery use this molecule to build libraries of IND candidates with defined chiral centers, vital for in vitro and in vivo screening campaigns. By integrating this intermediate, medicinal chemists can reliably access complex scaffolds, ensuring study compounds meet regulatory and analytical benchmarks.

Industry compliance standards

• OECD GLP (Good Laboratory Practice)
• EMA “Guideline on the Requirements for Chemical and Pharmaceutical Quality Documentation Concerning Investigational Medicinal Products”
• FDA IND Submission Guidelines
• ISO/IEC 17025:2017 for analytical method validation

Typical usage ratio

• 0.2–0.35 equivalents relative to varied core structures; ratio depends on combinatorial synthesis scale and core scaffold complexity

Downstream process integration

• Introduced post-lead identification as a coupling partner during fragment-based library elaboration, or direct integration in Suzuki or Buchwald–Hartwig cross-coupling steps to generate diverse investigational candidates

Final product types

• Chiral analogues in exploratory compound sets
• Validated IND candidates for early-phase clinical evaluation
• Small-molecule screening tools for biochemical assays

3. Intermediate for Fine Chemical Synthesis in Agrochemical R&D

Leading agrochemical companies employ this intermediate during the construction of enantioselective scaffolds for advanced crop protection agents and pheromone analogues. The carbamate group confers both reactivity and selectivity, supporting controlled functional group transformations without compromising stereochemistry.

Industry compliance standards

• FAO/WHO JMPR requirements for technical-grade intermediates
• ISO 9001:2015 for quality management during pilot-scale production
• REACH Annex VIII for registered chemical intermediates
• OECD TG 105 and TG 106 for metabolite traceability

Typical usage ratio

• 0.1–0.3 molar equivalents, refined during process optimization according to bioactivity screening results for new candidates

Downstream process integration

• Loaded after the main skeleton assembly step; frequently enters via selective deprotection and subsequent conjugation with bioactive moieties under anhydrous or inert conditions

Final product types

• Lead agrochemical candidates in insecticide and fungicide pipeline development
• Pheromone-mimicking compounds for integrated pest management trials
• Stereochemically pure precursors for registration batches

4. Protected Amine Source for Advanced Material Science Synthesis

Materials chemists incorporate this compound into the synthesis of specialty polymers and functionalized small-molecule monomers, where precise amine protection and deprotection control mechanical and electronic properties. Its steric features maintain desired configuration, supporting downstream polymerization or cross-linking reactions.

Industry compliance standards

• ISO 10993-1 for preliminary biocompatibility assessment (when used in biomedical materials development)
• ISO 14001:2015 for responsible chemical use in R&D labs
• EU RoHS Directive (if targeting electronics or sensor materials)
• GMP for pharmaceutical-grade material synthesis (where relevant)

Typical usage ratio

• 0.08–0.22 weight percent in functional monomer batch, modulated by polymer backbone requirements and degree of functionalization targeted

Downstream process integration

• Employed in the monomer functionalization phase prior to free-radical polymerization or used in post-polymerization modification for surface-active material preparation

Final product types

• Specialty copolymers for biomedical research
• Sensor-responsive surface coatings
• Prototype conductive and insulative films